Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort
第一作者机构:[1]Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Wang J.,Fang J.,Shou T.,et al.Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort[J].JOURNAL OF THORACIC ONCOLOGY.2025,20(3):
APA:
Wang, J.,Fang, J.,Shou, T.,Yang, N.,Wang, Q....&Chen, Z..(2025).Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort.JOURNAL OF THORACIC ONCOLOGY,20,(3)
MLA:
Wang, J.,et al."Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort".JOURNAL OF THORACIC ONCOLOGY 20..3(2025)